Skip to content
lifestyle.projectdiaspora.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
BeyondSpring, Inc.
BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value
June 4, 2026
BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026
June 2, 2026
BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting
May 21, 2026
BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update
May 21, 2026
BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs
May 5, 2026
BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026
May 2, 2026
BeyondSpring Files 2025 Annual Report on Form 10-K
May 1, 2026
BeyondSpring Reports 2025 Year-End Financial Results
May 1, 2026
BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference
February 11, 2026